Learn more →
Back to Expert Scholars
clinical / clinicalskin cancer

Anne Lynn S. Chang

安妮·林·张

MD

🏢Stanford University School of Medicine(斯坦福大学医学院)🌐USA

Associate Professor of Dermatology; Director, High Risk Skin Cancer Clinic皮肤科副教授;高风险皮肤癌诊所主任

52
h-index
2
Key Papers
2
Awards
2
Key Contributions

👥Biography 个人简介

Anne Lynn Chang is a dermatologic oncologist and Associate Professor at Stanford University with specialized expertise in advanced basal cell carcinoma. She was among the first investigators to study vismodegib and sonidegib in clinical trials, contributing to their regulatory approvals. Her laboratory and clinical work spans Hedgehog pathway biology in skin carcinogenesis, drug resistance mechanisms to smoothened inhibitors, and the emerging role of cemiplimab for BCC patients progressing on Hedgehog-targeted therapy.

Share:

🧪Research Fields 研究领域

Basal Cell Carcinoma基底细胞癌
Vismodegib Hedgehog Inhibitor维莫德吉Hedgehog抑制剂
Sonidegib索尼地吉
Gorlin SyndromeGorlin综合征
Advanced BCC Immunotherapy晚期基底细胞癌免疫治疗

🎓Key Contributions 主要贡献

Hedgehog Inhibitor Clinical Development

Participated in early phase trials of vismodegib and sonidegib at Stanford, helping establish efficacy and safety data that supported FDA approvals for locally advanced and metastatic basal cell carcinoma.

Drug Resistance in Advanced BCC

Characterized mechanisms of acquired resistance to smoothened inhibitors including SMO mutations and alternative Hedgehog pathway activation, informing strategies for sequential and combination therapies.

Representative Works 代表性著作

[1]

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

The Lancet Oncology (2021)

Pivotal trial demonstrating cemiplimab activity in advanced BCC patients who progressed on or were intolerant to Hedgehog pathway inhibitors, leading to FDA approval.

[2]

Resistance to vismodegib in advanced basal cell carcinoma: mechanisms and clinical implications

JAMA Dermatology (2022)

Comprehensive analysis of smoothened mutations and bypass pathway activation underlying clinical resistance to vismodegib in advanced BCC.

🏆Awards & Recognition 奖项与荣誉

🏆American Skin Association Research Scholar Award
🏆Stanford Medicine Dean's Award for Clinical Research

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 安妮·林·张 的研究动态

Follow Anne Lynn S. Chang's research updates

留下邮箱,当我们发布与 Anne Lynn S. Chang(Stanford University School of Medicine)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment